National PBM Monograph Template

A total of 383 patients received ambrisentan for a mean duration of 38.6 ±26.5 weeks, including 22 patients who received at least one dose of ambrisentan but did not enroll in ARIES-E. Comparisons of adverse events between doses are limited, as dosage adjustments were permitted after 24 weeks. ................
................